Self-immolative PEGylated dendritic drug conjugates for cancer therapy with enhanced cellular uptake

Abstract

A hypoxia-responsive nanomedicine NM-CB/Ce6 with prominent biocompatibility for co-delivering chlorambucil (CB) and chlorin e6 (Ce6) was prepared using a self-immolative PEGylated dendritic drug conjugate block-dendritic-polymer. Upon 650 nm near-infrared light (NIR) irradiation, the encapsulated Ce6 consumes oxygen to generate singlet oxygen (1O2) for photodynamic therapy (PDT). Under NIR-induced aggravated hypoxia, this nanomedicine can facilitate cellular internalization owing to hypoxia-responsive dePEGylation, and further disintegrate inside HepG2 cells to rapidly release activated CB for chemotherapy (CT).

Graphical abstract: Self-immolative PEGylated dendritic drug conjugates for cancer therapy with enhanced cellular uptake

Supplementary files

Article information

Article type
Communication
Submitted
16 May 2025
Accepted
09 Jun 2025
First published
10 Jun 2025

Chem. Commun., 2025, Advance Article

Self-immolative PEGylated dendritic drug conjugates for cancer therapy with enhanced cellular uptake

Z. Xia, Y. Zhang, X. Zuo, S. Cheng, Y. Tian and Y. Ding, Chem. Commun., 2025, Advance Article , DOI: 10.1039/D5CC02776D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements